Cancer claims, CBDs and SARMs highlights of 2017 enforcement picture
The picture painted by warning letters issued by FDA in 2017 is a chiaroscuro of old and new. Familiar enforcement action on claims language contrasted with warnings on the use of new, unapproved ingredients.